This confirmed that the small molecule inhibitor vismodegib potentiated the effects of topotecan, via targeting of the hedgehog pathway as an integrated mechanism together with topoisomerase-1 inhibition in the treatment of MYCN amplified, therapy-resistant neuroblastoma. Here, MYCN is linked to neuroblastoma.